Sign In
Buy KOD
$33.87
+0.655 (+1.97%)
At Close: Jun 03, 2026
Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus
11:38am, Tuesday, 10'th Aug 2021
Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.
Kodiak Sciences Has Declined $125M Funding From Baker Bros Citing Strong Balance Sheet
07:33am, Friday, 23'rd Jul 2021
In December 2019, Kodiak Sciences Inc (NASDAQ: KOD) entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed to fund up to $225 million in exchange for the right to 4
Kodiak Sciences to Present at Upcoming Conferences
07:00pm, Thursday, 20'th May 2021
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Kodiak Sciences Inc. - KOD
02:00am, Tuesday, 18'th May 2021
NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors are advised t
Kodiak Sciences (KOD) Q1 Earnings Miss, KSI-301 in Focus
12:02pm, Tuesday, 11'th May 2021
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
Why Kodiak Sciences Stock Is Tumbling Today
12:30pm, Monday, 10'th May 2021
The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.
Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights
05:30am, Monday, 10'th May 2021
PALO ALTO, Calif., May 10, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
What Makes Kodiak Sciences Inc. (KOD) a New Buy Stock
12:47pm, Tuesday, 04'th May 2021
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kodiak Sciences to Present at Upcoming Conferences
06:59pm, Wednesday, 21'st Apr 2021
PALO ALTO, Calif., April 21, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics
Kodiak Sciences Offers Multiple Shots On Goal For Eye Treatments, Multiple Catalysts Expected In 2022
09:46am, Monday, 15'th Mar 2021
Kodiak Sciences is expected to have three trial readouts in 2022 with use of its drug KSI-301. If all studies end up being successful, then 3 BLA filings would happen.
Nielsen, Nordstrom, PayPal and More Friday Afternoon Analyst Calls
12:02pm, Friday, 12'th Mar 2021
With the trading day nearing halfway over, the broad markets were somewhat mixed to close out the week.
Kodiak Sciences (KOD) Misses on Q4 Earnings, KSI-301 in Focus
11:22am, Tuesday, 02'nd Mar 2021
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
05:30am, Monday, 01'st Mar 2021
PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
Kodiak Sciences' KSI-301 Shows Durable Benefit In Retinal Disease Settings
06:07am, Tuesday, 16'th Feb 2021
Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biop
Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting
08:28am, Saturday, 13'th Feb 2021
PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to
